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Type 2 diabetes is 2–3 times more prevalent in people of South Asian and African/African
Caribbean ethnicity than people of European ethnicity living in the UK. The former 2 groups
also experience excess atherosclerotic cardiovascular disease (ASCVD) complications of
diabetes. We aimed to study ethnic differences in statin initiation, a cornerstone of ASCVD
primary prevention, for people with type 2 diabetes.
Methods and findings
Observational cohort study of UK primary care records, from 1 January 2006 to 30 June 2019.
Data were studied from 27,511 (88%) people of European ethnicity, 2,386 (8%) people of
South Asian ethnicity, and 1,142 (4%) people of African/African Caribbean ethnicity with inci-
dent type 2 diabetes, no previous ASCVD, and statin use indicated by guidelines. Statin initia-
tion rates were contrasted by ethnicity, and the number of ASCVD events that could be
prevented by equalising prescribing rates across ethnic groups was estimated. Median time to
statin initiation was 79, 109, and 84 days for people of European, South Asian, and African/Afri-
can Caribbean ethnicity, respectively. People of African/African Caribbean ethnicity were a
third less likely to receive guideline-indicated statins than European people (n/N [%]: 605/1,142
[53%] and 18,803/27,511 [68%], respectively; age- and genderAU : Thepaperusedboththetermsgenderandsextorefertothesamefactor:Istandardizedtogenderbecausethistermwasusedmoreoften; includinginFig1:Ifitshouldinsteadbesex; pleaseeditthroughout; includinginFig1:-adjusted HR 0.67 [95% CI
0.60 to 0.76], p < 0.001). The HR attenuated marginally in a model adjusting for total choles-
terol/high-density lipoprotein cholesterol ratio (0.77 [95% CI 0.69 to 0.85], p < 0.001), with no
further diminution when deprivation, ASCVD risk factors, comorbidity, polypharmacy, and
healthcare usage were accounted for (fully adjusted HR 0.76 [95% CI 0.68, 0.85], p < 0.001).
People of South Asian ethnicity were 10% less likely to receive a statin than European people
(1,489/2,386 [62%] and 18,803/27,511 [68%], respectively; fully adjusted HR 0.91 [95% CI
0.85 to 0.98], p = 0.008, adjusting for all covariates). We estimated that up to 12,600 ASCVD
events could be prevented AU : Forthestatementupto12; 600ASCVDeventscouldbeprevented; Irecommendindicatingoverwhattimeperiod:over the lif tim s of pe ple currently affected by type 2 diabetes in
the UK by equalising statin prescribing across ethnic groups. Limitations included incomplete-
ness of recording of routinely collected data.
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Conclusions
In this study we observed that people of African/African Caribbean ethnicity with type 2 dia-
betes were substantially less likely, and people of South Asian ethnicity marginally less
likely, to receive guideline-indicated statins than people of European ethnicity, even after
accounting for sociodemographics, healthcare usage, ASCVD risk factors, and comorbidity.
Underuse of statins in people of African/African Caribbean or South Asian ethnicity with type
2 diabetes is a missed opportunity to prevent cardiovascular events.
Author summary
Why was this study done?
• People of South Asian and African/African Caribbean ethnicity living in the UK are
more likely to have type 2 diabetes than people of European ethnicity, and have higher
rates of cardiovascular complications, e.g., heart attacks and strokes.
• Lowering blood cholesterol with statin treatment reduces cardiovascular complications,
but previous studies suggest ethnic differences exist in statin prescribing for people with
diabetes.
• However, no study has sought explanations for identified ethnic differences, or
accounted for changes in prescribing guidelines, so we aimed to provide a timely, repre-
sentative assessment of ethnic differences in guideline-indicated statin prescribing in
type 2 diabetes.
What did the researchers do and find?
• We identified people with newly diagnosed type 2 diabetes in primary care eligible for
statin treatment for primary prevention of cardiovascular disease, then compared rates
of statin initiation for people of European, South Asian, and African/African Caribbean
ethnicity.
• People of African/African Caribbean ethnicity with type 2 diabetes were 24% less likely
to receive guideline-indicated statin treatment than people of European ethnicity, and
people of South Asian ethnicity 9% less likely.
• Ethnic differences remained after allowing for differences in cholesterol levels, other
cardiovascular risk factors, demographic factors, deprivation, healthcare usage, comor-
bidity, and polypharmacy.
• We estimated that equalising statin prescribing rates across these 3 ethnic groups would
prevent up to 12,600 heart attacks and strokes over the lifetimes AU : Pleasecheckthatoverthelifetimesiscorrecthere; ifyouaddinformationaboutoverwhattimeperiodelsewhereinthepaper; assuggested:of peopl currently
affected by type 2 diabetes in the UK.
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What do these findings mean?
• People with type 2 diabetes of African/African Caribbean and South Asian ethnicities
are less likely to be prescribed a statin for primary prevention of cardiovascular disease
in the UK than people of European ethnicity.
• Policies to increase statin use among people of African/African Caribbean and South
Asian ethnicity with type 2 diabetes could substantially reduce the excess burden of car-
diovascular events in these groups.
Introduction
Type 2 diabetes is a potent risk factor for cardiovascular disease, itself causing 17.9 million
deaths worldwide per year, 80% of which are due to myocardial infarction and stroke com-
bined [1]. People of South Asian and African/African Caribbean ethnicity living in the UK
experience not only a 3-fold higher prevalence of type 2 diabetes [2], but higher rates of the
atherosclerotic cardiovascular disease (ASCVD, i.e., coronary heart disease and stroke) com-
plications of diabetes than their European-origin counterparts [3]. Explanations for this are
unclear but may relate to poorer control of modifiable ASCVD risk factors, such as hypercho-
lesterolaemia, in South Asian and African/African Caribbean groups [4–6]. Statin treatment is
a crucial tool in reducing ASCVD risk in diabetes; the Collaborative Atorvastatin Diabetes
Study (CARDS) trial demonstrated a 37% reduction in ASCVD events over 4 years of follow-
up [7]. In the UK, statin prescribing in people with diabetes occurs in primary care and is gov-
erned by the National Institute for Health and Care Excellence (NICE) guidelines [8–10].
NICE guidelines have varied by time period regarding thresholds for statin prescription; the
2006 guideline designated type 2 diabetes a secondary prevention state and thus advocated
universal prescription [9], the 2008 guideline recommended statin use in all�40 years old or
with a 10-year ASCVD risk of�20% or with�1 other ASCVD risk factor [8], whilst the 2014
guideline advised high-intensity statin prescription (e.g., atorvastatin 20 mg) simply for all
with a 10-year ASCVD risk of�10% [10] (diabetes at this point being a multiplier in the rec-
ommended ASCVD risk equation).
Despite ethnic differences in diabetes risk and resultant ASCVD risk, as far as we know
only 2 UK studies have examined ethnic differences in statin prescribing for primary preven-
tion in diabetes. In a 2007 study of 36 practices in South London, Millett et al. [5] AU : Iaddedref ½5�forMillettetal:Ifref ½5�isnotthecorrectrefforthisstatement; pleasechangetocorrectref :described
lower rates of statin prescription in people with diabetes of black African origin than in their
white counterpartsAU : Ichangedwhitegroupstointheirwhitecounterparts:Ifthisisnotcorrect; pleaseedit:(49% versus 64%), though prescribing was gen ally imilar for South
Asian and white people. Comparable findings were reported from a 2007 study based on data
from the Health Survey for England [6]. Furthermore, several US studies of health record data
indicate substantial underprescribing of statins to African American people with diabetes in
whom statins are indicated, in comparison to their white counterparts [11–14], though we are
unaware of any similar North American data for people of South Asian ethnicity. Evidence
suggests statins are equally effective in people of European, South Asian, and African/African
Caribbean ethnicity [15], so there is no rationale for restricting their use on the basis of
ethnicity.
However, to our knowledge, there are no studies of ethnic differences in statin prescribing
for type 2 diabetes using nationally representative datasets, exploring reasons for prescribing
differences, restricting analysis to people with guideline indications for statin use (as opposed
PLOS MEDICINE Ethnic differences in statin prescribing
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003672 June 29, 2021 3 / 18
to everyone with diabetes), or employing data from after the 2014 NICE guideline changes in
statin prescribing [10].
Therefore, using a nationally representative database of prescribing records, we aimed to
study ethnic differences in statin initiation for the statin-eligible (according to guidelines [10])
population with type 2 diabetes. Specifically, we (i) contrasted statin initiation rates for people
of European, South Asian, and African/African Caribbean ethnicity, (ii) sought explanations
for differences found, and (iii) estimated the population impact of equalising statin prescribing
for the UK’s 3 main ethnic groups.
Methods
Study population
We used data from the Clinical Practice Research Datalink (CPRD), a national database of
over 12 million anonymised primary care records from 836 practices [16]. CPRD is represen-
tative of the UK population with regards to age, gender, and ethnicity [16]. Derivation of the
study cohort required several steps (Table 1). First, we applied a diabetes diagnostic adjudica-
tion algorithm, based on a previously published version [17], to the population of individuals
in CPRD with European, South Asian, or African/African Caribbean ethnicity Read codes (see
below) to obtain those with type 2 diabetes. We then limited this to an adult (�18 years) cohort
of individuals whose first diabetes diagnostic or medication code (i.e., their index date) was
after 1 January 2006 and over 12 months after the latest of (i) the patient’s current registration
date or (ii) the practice’s up to CPRD standard date. This was to ensure an ‘incident’ cohort,
i.e., to avoid including prevalent cases of diabetes that were recorded soon after the individual
joined a new practice or the practice records met CPRD standards. We then excluded people
with prevalent ASCVD or statin use at the time of diabetes diagnosis. Following this, we
applied time-period-dependent criteria to select the population in whom statins were indi-
cated, using the 2006 NICE guideline [9] for people with index dates between 1 January 2006
and 31 May 2008 (all of whom were eligible for statin prescription, and thus inclusion), the
2008 guideline [8] for people with index dates between 1 June 2008 and 31 July 2014 (who
were eligible for statin prescription, and thus inclusion, if they were�40 years old or had a
10-year ASCVD risk of�20% or had�1 other ASCVD risk factor), and the 2014 guideline
[10] for people with index dates between 1 August 2014 and 30 June 2019 (who were eligible
for statin prescription, and thus inclusion, if they had a 10-year ASCVD risk of�10%) (see
Table 1). For the third time period, where the criterion for statin indication changed to a
10-year ASCVD risk score� 10%, the index date was changed to the date of the ASCVD risk
score� 10% record. People with prevalent ASCVD or statin use at their new index date were
once again excluded at this stage. The intention of examining statin initiation by time-varying
eligibility was to enhance the validity of the study by selecting a denominator sample for each
period that reflected appropriate prescribing at the time.
Outcome
Statin initiation was designated by a first ever statin prescription date on or after the index
date (i.e., the date when follow-up started). In all cases (i.e., for each of the 3 time periods per-
taining to 2006, 2008, and 2014 NICE guidelines), the index date was the date when the person
became eligible for statin treatment, according to the relevant guideline in use at the time (see
above). By using the first date of eligibility for statin treatment as the index date (irrespective
of what factors governed that eligibility), we aimed to produce a focused outcome of appropri-
ate prescribing. This enabled a fair comparison for the 3 ethnic groups across all time periods
of the proportion of those who should have received a statin who actually did so.
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Other lipid-lowering medications were not considered, since they are generally second-line
drugs (e.g., ezetimibe, for which there were very small numbers of incident prescriptions in
people not on statins: n = 38, n< 5, and n< 5 for people of European, South Asian, and Afri-
can/African Caribbean ethnicity, respectively) or their use falls outside of all NICE guidelines
Table 1. Derivation of cohort, by ethnicity.
European/South Asian/African/African Caribbean ethnicity codes in CPRD, n = 5,566,120
4,968,447 European (89%), 363,735 South Asian (7%), 233,938 African/African Caribbean (4%)
#
Algorithm-adjudicated T2DM after 1 January 2006, n = 158,554
138,370 European (87%), 13,850 South Asian (9%), 6,334 African/African Caribbean (4%)
#
Adult (�18 years), incident cohort, n = 102,436
93,120 European (91%), 6,499 South Asian (6%), 2,817 African/African Caribbean (3%)
#
Exclude people with prevalent statin use or ASCVD, n = 56,291
49,724 European (88%), 4,451 South Asian (8%), 2,116 African/African Caribbean (4%)
#
T2DM index date 1 Jan 2006
to 31 May 2008,
n = 10,773
9,934 European (92%),




T2DM index date 1 Jun 2008 to 31 Jul 2014,
n = 30,512
26,799 European (88%),
2,544 South Asian (8%),
1,169 African/African Caribbean (4%)
#
T2DM index date 1 Aug 2014 to 30 Jun 2019,
n = 15,006
12,991 European (87%),
1,325 South Asian (9%),
690 African/African Caribbean (5%)
#
Statins indicated (NICE 2006








Statins indicated (NICE 2008 [8]) in all �40 years or 10-year
ASCVD risk� 20% or 1+ risk factors (family history of




2,544 South Asian (8%),
1,169 African/African Caribbean (4%)
#




328 South Asian (6%),
142 African/African Caribbean (3%)
#









ASCVD risk score date subsequent
to T2DM index date,
n = 2,378�
2,169 European (91%),
151 South Asian (6%),
58 African/African Caribbean (2%)
#
Exclude people with prevalent
statin use or ASCVD at ASCVD risk
score date, n = 2,000
1,833 European (92%), 119 South




40,963 European (89%), 3,413 South Asian (7%), 1,549 African/African Caribbean (3%)
#
Complete case analysis, n = 31,039
27,511 (89%) European, 2,386 South Asian (8%), 1,142 African/African Caribbean (4%)
ASCVD, atherosclerotic cardiovascular disease; CPRD, Clinical Practice Research Datalink; NICE, National Institute for Health and Care Excellence; T2DM, type 2
diabetes mellitus.
�These people were assigned a new index date equivalent to their ASCVD risk score date, and those with prevalent ASCVD/statin use at the new index date were
excluded.
https://doi.org/10.1371/journal.pmed.1003672.t001
PLOS MEDICINE Ethnic differences in statin prescribing
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003672 June 29, 2021 5 / 18
pertinent to the study, and thus they are rarely initiated in primary care. We did not examine
ethnic differences in statin prescribing for secondary prevention. This is an important, but dif-
ferent question and would have required a different approach, as initiation of statins for sec-
ondary prevention most commonly occurs in secondary care, making it difficult to establish
index dates of statin eligibility and initial prescription.
Covariates
The main exposure in this study was self-reported (i.e., assigned by the patient themselves)
European, South Asian, or African/African Caribbean ethnicity. Ethnicity is a complex con-
struct that groups people together who identify with each other through a shared culture, and
encompasses factors in common such as cultural heritage, ancestry, language, history, diet, or
religion [18,19]. Thus, it should be self-defined, according to the group the individual most
identifies with [20]. Ethnicity was designated using ethnicity Read codes, usually recorded by
primary care staff during a patient’s initial registration with a practice. Primary care practices
were financially incentivised to record ethnicity, under the Quality and Outcomes Framework
(QOF) [21], from 2006 to 2011. A previously published algorithm [22] adjudicated on cases of
multiple or differing codes per patient. This algorithm was also used to derive the following
ethnic sub-groups for sub-group analyses: British, Irish, other white, Indian, Pakistani, Bangla-
deshi, other South Asian, Caribbean, African, and other black (S1 Text). People with Read
codes indicating mixed ethnicity were excluded from this study.
Covariates were selected pragmatically (i.e., governed by what was available in the dataset)
to enable investigation of areas of potential confounding—sociodemographics (age, gender,
socioeconomic deprivation), ASCVD risk factors (smoking, total cholesterol/high-density
lipoprotein [HDL] cholesterol ratio [TC/HDL], BMI, antihypertensive use), healthcare usage
(consultation rate), comorbidity (4 chronic disease areas), and polypharmacy (number of
medications)—and to enable investigation of effect modification by degree of hyperlipidaemia,
geographical location (London versus non-London practice and country within the UK—
examined in separate sets of models), guideline time period, ethnic sub-group, and gender.
Age at index date was calculated by subtracting year of birth from year of index date. Gender
was self-reported male or female (no other categories were present in the dataset). Practice
location was studied by (i) London versus non-London practices and (ii) country within the
UK. Postcode-designated, quintilised Index of Multiple Deprivation (IMD) [23] data were
available at the practice level for the whole cohort, and at the individual level for 58%. Smoking
was categorised as never, ex, or current, based on Read codes up to 5 years prior to and prefer-
entially closest to the index date. Healthcare usage was categorised by quartile of the number
of patient-initiated consultations in the year before the index date, and polypharmacy by quar-
tile of the number of different medications prescribed in the year before the index date. Values
of HbA1c, BMI, and total and HDL cholesterol closest to the index date, in the 5 years preced-
ing it, were used.TC/HDL AU : Pleasecheckthattheeditstothesentence}TC=HDL:::}captureyourmeaning:Ifnot; pleaseprovidecorrectwording:and non-HDL (to al chol ster l minus HDL cholesterol) v lues
were derived from the recorded total and HDL cholesterol values. Prevalent comorbidity (can-
cer, asthma/chronic obstructive pulmonary disease [COPD], chronic kidney disease [CKD],
and serious mental illness) and antihypertensive use were determined at index date. For those
who did not receive a statin throughout follow-up, presence of a recorded reason for statin
declinature was noted (this variable consisted ofAU : Ichangedconflatedtoconsistedof ðtoavoidmisreadingbecauseoftheothermeaningofconflate : toconfuseÞ:the presence of 1 or more of the foll wing
codes in the health record: statin contraindicated [3%], statin declined [80%], statin not toler-
ated [21%], statin purchased over the counter [1%]). Finally, Read codes indicating exception
reporting (i.e., exclusion) from the diabetes QOF (the system by which primary care physicians
are incentivised to record treatment metrics on their patients) were noted.
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Statistical analysis
All analytic methods were pre-specified in a scientific protocol (S1 Protocol).
Complete case analysis (i.e., inclusion of data only from people with complete recording of all
baseline covariates) was used for all baseline covariates in the main models. We chose this
approach over multiple imputation as the missing at random assumption (necessary for multiple
imputation) may not hold in primary care records (e.g., BMI is more likely to be recorded if not in
the healthy range), and complete case analysis has been proven to be valid providing the missing-
ness is conditionally independent of the outcome [24]. Of note, most covariates of interest were
complete in our data: Ethnicity was required for inclusion in the study population; age, gender,
and deprivation had no missing data; and other variables were defined by presence/absence of spe-
cific codes in the health record (e.g., specific diagnoses or medications, healthcare usage), so could
not be missing. The only variables with missing data were therefore smoking status, TC/HDL, and
BMI, which relied solely on physicians’ recording, and thus were not complete for all individuals.
Baseline characteristics were compared by ethnicity, adjusting means for age, or using propor-
tions age-standardised to the CPRD population. Additionally, characteristics, where available,
were compared between the complete case analysis sample and the sample for which some data
were missing, to explore important differences between those with and without missing data.
The pre-specified primary comparison of statin initiation in people of South Asian or Afri-
can/African Caribbean versus European ethnicity was studied using multilevel Cox propor-
tional hazards models with robust standard errors to account for within-practice clustering of
prescribing patterns. Prescribing behaviour is similar for doctors working in the same practice
[25] (i.e., clustering of prescribing patterns), resulting in individuals attending the same prac-
tice not being independent of each other with respect to statin initiation, which may in turn
lead to underestimation of standard errors, i.e., excess type 1 errors. To counteract this, we fit-
ted models using robust standard errors, with practice as the cluster variable. Follow-up was
censored at the earliest date of the following: statin initiation, the study end date, death, or
leaving a CPRD practice. Models were adjusted for age and gender, plus additional factors in
turn separately (deprivation, smoking, healthcare usage, TC/HDL, BMI, comorbidity [com-
prising cancer, asthma/COPD, CKD, and serious mental illness, entered as separate individual
terms], polypharmacy, and antihypertensive use), then finally all factors together. We evalu-
ated the likelihood of the results indicating a true ethnic difference chiefly via inspection of the
95% confidence intervals of a given association [26], generated using standard errors from the
2-sided z test from Cox regression models.
The proportional hazards assumption was verified by inspection of log–log survival plots by
ethnic group and performing a formal test of Schoenfeld residuals. Collinearity was investi-
gated between variables for the model containing all covariates by calculating variance infla-
tion factors (VIFs), and variables with VIF� 10 were excluded in sensitivity analyses to assess
the impact on standard errors.
Pre-specified secondary sub-group analyses were performed, by inspecting both within-
group HRs and ethnicity × sub-group interaction terms, to study whether ethnic differences in
statin prescribing varied by (i) baseline TC/HDL tertile, (ii) London practice locationAU : IchangedLondonresidencetoLondonpracticelocation:Ifthisisnotcorrect; pleaseedit:, (iii)
time period in relation to NICE guidelines (i.e., 1 January 2006–31 May 2008, 1 June 2008–31
July 2014, or 1 August 2014–30 June 2019), (iv) ethnic sub-group, (v) age group at index date
(�45 years, >45 to�65 years, or >65 years), (vi) country (England, Scotland, and Wales only,
due to small numbers in Northern Ireland), and (vii) gender. Where major differences in statin
initiation were shown, we compared baseline characteristics between sub-groups. Pre-speci-
fied secondary sensitivity analyses explored the impact of adjustment for further factors—
HbA1c, patient-level IMD, non-HDL cholesterol, and BMI categories (using cut points of
PLOS MEDICINE Ethnic differences in statin prescribing
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25 kg/m2 to designate overweight and 30 kg/m2 to designate obesity in people of European eth-
nicity, and cut points of 23 kg/m2 and 27.5 kg/m2 in people of South Asian or African/African
Caribbean ethnicity [27])—or exclusion of people who gave a reason for declining a statin or
who were excepted from the diabetes QOF.
Finally, we estimated the population impact of equalising statin prescribing across ethnic
groups by comparing the number of ASCVD events prevented at observed statin initiation
rates for people of European ethnicity with those at observed statin initiation rates for people
of South Asian and African/African Caribbean ethnicity, using estimated populations of peo-
ple with type 2 diabetes in the latter 2 ethnic groups as the denominators, and a range of
assumptions regarding statin potency and adherence.
This study is reported as per the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guideline (S1 Checklist).
Analyses were carried out using Stata, version 16.
Ethical approval
Ethical approval for this study was obtained from the Independent Scientific Advisory Com-
mittee (protocol 19_045AU : ISACprotocolgivenas17045intheMethods; but19045inthetitleofS1Protocol:Pleasefixwhicheveroneisincorrect:, see protocol in S1 Protocol) and the Lond n School of Hygi ne &
Tropical Medicine (project ID 14222).
Patient and public involvement
There was no patient or public involvement in developing the research question, designing or
conducting the study, interpreting the findings, or disseminating the results.
Results
The study population comprised 27,511 (88%) people of European ethnicity, 2,386 (8%) people
of South Asian ethnicity, and 1,142 (4%) people of African/African Caribbean ethnicity who
were eligible for guideline-indicated statin initiation (Table 1), with a median follow-up time
of 0.7 years (interquartile range 0.07–2.44 years). People with missing ethnicity (n = 25,847)
were excluded from the study population, but comparisons with the European ethnic group
are presented in S4 and S5 Tables. Statin initiation rates were lower in people of South Asian
and African/African Caribbean than European ethnicity (n [%] and rate per 1,000 person-
years at risk: 1,489 [62%] and 0.36 [95% CI 0.34 to 0.37] for people of South Asian ethnicity,
605 [53%] and 0.24 [95% CI 0.22 to 0.26] for people of African/African Caribbean ethnicity,
and 18,803 [68%] and 0.40 [95% CI 0.39 to 0.41] for people of European ethnicity). Median
time to statin initiation was 79 (IQR 7–368) days for people of European ethnicity, and 109
(IQR 6–418) and 84 (IQR 2–520) days for South Asian and African/African Caribbean groups,
respectively.
Mean age at diabetes onset was markedly lower in people of South Asian and African/Afri-
can Caribbean ethnicity than those of European ethnicity (50 years and 52 years versus 59
years, respectively), and higher proportions of the former groups attended a practice in Lon-
don AU : IchangedwereLondonresidenttoattendedapracticeinLondon:Ifthisisnotcorrect; pleaseedit:and in t e most deprive IMD quin ile (Table 2). How ver, ASCVD ri k fact s were in
general more favourable for the South Asian and African/African Caribbean groups than the
European group (notably, lower levels of baseline cholesterol)—the exception to this was anti-
hypertensive use, which was far higher in people of African/African Caribbean origin than in
the other groups. There were no consistent ethnic differences in healthcare usage or comorbid-
ity. After exclusion of people with missing data for TC/HDL (n = 10,276, 22%), BMI (n =
3,723, 9%), and smoking (n = 887, 3%), 68% of the sample (n = 31,039) remained for the com-
plete case analysis (Table 1). A comparison of baseline characteristics by inclusion versus
PLOS MEDICINE Ethnic differences in statin prescribing
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003672 June 29, 2021 8 / 18
Table 2. Baseline characteristics of people with incident type 2 diabetes in 2006 or later AU : InthetitletoFig2; Ichangedafter2006toin2006orlaterforconsistencywithdatesgivenelsewhereinthepaper:with no prior stat n use or ASCVD, by e h icity (complete ca e anal sis).
European ethnicity South Asian ethnicity African/African Caribbean
ethnicity
N (%) 27,511 (88) 2,386 (8) 1,142 (4)
Ethnic sub-group British: 26,238 (95); Irish: 257 (1);
other/not stated white: 1,016 (4)
Indian: 932 (39); Pakistani: 628 (26);
Bangladeshi: 213 (9); other/not stated South
Asian: 612 (26)
Caribbean: 420 (37); African: 553
(48); other/not stated black: 170
(15)
Age, years 59 ± 12 50 ± 11 52 ± 11
Age group
�45 years 4,009 (15) 888 (37) 307 (27)
>45 to�65 years 15,505 (56) 1,276 (53) 679 (59)
>65 years 7,997 (29) 222 (9) 156 (14)
Gender
Male 15,249 (53) 1,307 (53) 589 (51)
Female 12,262 (47) 1,079 (47) 553 (49)
Practice location
Non-London 24,861 (91) 1,467 (66) 440 (44)
London 2,650 (9) 919 (34) 702 (56)
Country
England 19,205 (68) 2,163 (90) 1,093 (95)
Scotland 5,464 (20) 128(4) 25 (2)
Wales 2,540 (10) 93(5) 21 (3)
Northern Ireland 302 (2) 2 (0.01) 3 (0.01)
Deprivation—practice IMD quintile
1 (least deprived) 3,766 (12) 203 (7) 46 (3)
2 4,713 (15) 287 (11) 108 (10)
3 5,130 (18) 505 (19) 182 (15)
4 6,118 (22) 700 (26) 360 (30)
5 (most deprived) 7,784 (32) 691 (37) 446 (42)
Deprivation—patient IMD quintile�
1 (least deprived) 2,754 (15) 184 (9) 30 (3)
2 3,230 (18) 291 (16) 79 (8)
3 3,089 (20) 334 (17) 158 (17)
4 3,141 (22) 411 (29) 233 (26)
5 (most deprived) 3,107 (24) 464 (30) 367 (46)
Smoking
Never 9,829 (38) 1,510 (61) 665 (58)
Ex 12,721 (39) 567 (23) 350 (29)
Current 4,961 (23) 309 (16) 127 (13)
Number of consultations in previous
year
7 (4–12) 6 (3–10) 6 (3–10)
Number of consultations in previous
year—quartiles
1 (0 to 3 consultations) 5,901 (21) 607 (27) 309 (24)
2 (4 to 7 consultations) 8,540 (29) 772 (29) 373 (28)
3 (8 to 12 consultations) 6,702 (24) 577 (29) 250 (19)
4 (13+ consultations) 6,368 (25) 430 (16) 210 (29)
Total HDL cholesterol, mmol/l 4.96 ± 1.59 4.67 ± 1.45 4.21 ± 1.43
Non-HDL cholesterol, mmol/l 4.38 ± 1.18 4.16 ± 1.04 3.97 ± 1.12
HbA1c, percent
�� 7.8 ± 2.1 7.6 ± 2.0 7.8 ± 2.3
(Continued)
PLOS MEDICINE Ethnic differences in statin prescribing
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003672 June 29, 2021 9 / 18
exclusion in the complete case analysis demonstrated no obvious incongruities, except for
lower consulting rates and antihypertensive usage in the latter group (S1 Table). Importantly,
missingness did not differ greatly by ethnicity (33% for the European, 31% for the South
Asian, and 28% for the African/African Caribbean group).
In age- and gender-adjusted models of ethnic differences in statin initiation for the guide-
line-eligible population, people of African/African Caribbean ethnicity were 33% less likely
than people of European ethnicity to receive statin treatment (HR 0.67 [95% CI 0.60 to 0.76],
p< 0.001), and people of South Asian ethnicity were 12% less likely (0.88 [95% CI 0.82 to
0.93], p< 0.001) (Fig 1). These differences were unaffected by further adjustment for depriva-
tion, smoking, healthcare usage, BMI, comorbidity, or polypharmacy. However, accounting
for baseline TC/HDL reduced ethnic differences (South Asian versus European, HR 0.93 [95%
Table 2. (Continued)
European ethnicity South Asian ethnicity African/African Caribbean
ethnicity
HbA1c, mmol/mol
�� 61 ± 23 59 ± 23 60 ± 25
BMI, kg/m2 34 ± 7 28 ± 6 31 ± 6
Underweight/normal 2,262 (9) 183 (12) 34 (5)
Overweight��� 7,074 (21) 679 (25) 205 (17)
Obese��� 18,175 (71) 1,524 (63) 903 (78)
CKDAU : InTable2; IchangedCKDReadcodetoCKD; tomatchtheformatoftheothercomorbiditiesinthetable:Ifthisisnotcorrect;pleaseedit:1,058 (4) 41 (3) 50 (6)
Cancer 1,902 (6) 48 (2) 56 (6)
Asthma/COPD 4,175 (17) 307 (17) 131 (12)
Serious mental illness 1,405 (7) 74 (4) 63 (7)
Number of different medications
prescribed in previous year
6 (3–10) 5 (2–9) 5 (2–9)
Number of different medications
prescribed in previous year—quartiles
1 (0 to 2 medications) 5,527 (20) 605 (22) 287 (23)
2 (3 to 5 medications) 7,607 (27) 620 (22) 333 (25)
3 (6 to 9 medications) 6,929 (25) 552 (29) 267 (21)
4 (10+ medications) 7,448 (28) 609 (28) 255 (31)
Antihypertensive use 12,477 (36) 620 (29) 516 (41)
Recorded reason for statin declinature
(if statin not prescribed)����
1,181/8,708 (10) 66/897 (6) 30/537 (4)
Exception reported from diabetes
Quality and Outcomes Framework
1,186 (6) 102 (7) 54 (5)
Time period of index date, by NICE
guideline
1 Jan 2006 to 31 May 2008 5,583 (20) 339 (14) 167 (15)
1 Jun 2008 to 31 Jul 2014 17,849 (65) 1,791 (75) 856 (75)
1 Aug 2014 to 30 Jun 2019 4,079 (15) 256 (11) 119 (10)
Data are n (age-standardised percent), n/N (age-standardised percent), AU : InthelegendtoTable2; Iaddedn=Nðage   standardisedpercentÞtothelistofdatatypesinthetable forstatindeclinature:Ifthisisnotcorrect;pleaseedit:age-adjusted m an ± SD, or median (IQR).
ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HbA1c,
glycosylated haemoglobin A1c; HDL, high-density lipoprotein; IMD, Index of Multiple Deprivation; NICE, National Institute for Health and Care Excellence.
�Data available for a subset of 15,321 people of European ethnicity, 1,684 people of South Asian ethnicity, and 867 people of African/African Caribbean ethnicity.
��Data available for a subset of 16,889 people of European ethnicity, 1,669 people of South Asian ethnicity, and 769 people of African/African Caribbean ethnicity.
���BMI cut points for overweight and obesity, respectively, were 25 kg/m2 and 30 kg/m2 for people of European ethnicity and 23 kg/m2 and 27.5 kg/m2 for people of
South Asian or African/African Caribbean ethnicity.
����Reasons included the following: statin contraindicated, statin not tolerated, statin declined, or statin purchased over the counter.
https://doi.org/10.1371/journal.pmed.1003672.t002
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CI 0.87 to 0.99], p = 0.02; African/African Caribbean versus European, HR 0.77 [95% CI 0.69
to 0.85], p< 0.001), with no further attenuation seen when all available baseline covariates
were added to the model (HR 0.91 [95% CI 0.85 to 0.98], p = 0.01, and HR 0.76 [95% CI 0.68,
0.85], p< 0.001, respectively).
Secondary sub-group analyses showed that ethnic differences in statin initiation appeared
to be more pronounced at the lowest and, for people of African/African Caribbean ethnicity,
highest tertile of TC/HDL (African/African Caribbean ethnicity × TC/HDL tertiles 2 and 3,
interaction p = 0.15 and p = 0.63, respectively; Fig 2). People of African/African Caribbean eth-
nicity in the highest TC/HDL tertile were more likely to be younger, with more adverse
ASCVD risk factors (S2 Table). Ethnic differences in statin initiation seemed to be greatest for
people attending practices outside LondonAU : IchangedlivingoutsideLondonandlivinginLondontoattendingpracticesoutsideLondonandattendingpracticesinLondon; respectively:Ifthisisnotcorrect; pleaseedit:—indeed, for South Asian pe ple attend ng prac-
tices in London, prescribing rates equalled those of European people (location × ethnicity,
interaction p = 0.04; Fig 2). Similarly, ethnic differences appeared less marked for the last 5
years of the study, though there was no statistical evidence of interaction by calendar period
(ethnicity × last time period, interaction p = 0.24 for South Asian people and p = 0.51 for Afri-
can/African Caribbean people); these findings should be interpreted with caution as confi-
dence intervals were very wide due to low power, and do in fact include the larger differences
present for the prior periods. Of note, risks of underprescription appeared more distinct in
certain ethnic sub-groups, i.e., for the ‘other white’ compared to the British group, for people
of Bangladeshi compared to Indian or Pakistani ethnicity, and for the ‘other black’ compared
to the Caribbean or African groups. Comparison of baseline characteristics between the sub-
groups demonstrated that groups with lower statin initiation rates were, in general, more likely
to be younger and more deprived, with higher TC/HDL and less healthcare utilisation (S3
Table).
Results of further secondary sub-group analyses by age group, country, and gender (S1 Fig),
and of sensitivity analyses adjusting for HbA1c, patient-level deprivation, or BMI category or
excluding those with recorded reasons for statin declinature or who had been exception
Fig 1. Associations between ethnicity and guideline-indicated statin initiation after type 2 diabetes diagnosis.
Data are HRs (marker) and 95% CIs (capped lines), from multilevel models accounting for intra-practice clustering,
European ethnicity = referent category, i.e., HR for people of European ethnicity = 1. TC/HDL, total cholesterol/high-
density lipoprotein cholesterol ratio.
https://doi.org/10.1371/journal.pmed.1003672.g001
PLOS MEDICINE Ethnic differences in statin prescribing
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003672 June 29, 2021 11 / 18
reported from the diabetes QOF (S2 Fig), were similar to the results of the main analyses.
Inspection of log–log survival plots by ethnic group showed no major deviations from propor-
tionality (S3 Fig), but a formal test of Schoenfeld residuals revealed some evidence of non-pro-
portionality for both age and ethnicity. However, given that the ethnicity hazard ratios were
unaffected by the addition of interaction terms for age × time band (time bands were based on
tertiles of follow-up: 0–65 days, 66–586 days, and>586 days) or ethnicity × time band, and
remained similar when stratified by time band (S4 Fig), we considered the non-proportionality
minor enough to justify proceeding with Cox models. Collinearity diagnostics of the main
model featuring all covariates (i.e., the last model shown in Fig 1) revealed VIF� 10 for BMI
and TC/HDL, as well as the forced variables of age and gender. When BMI and TC/HDL were
removed from the model, the resulting deflation in standard errors was minimal and did not
affect the interpretation of the results; therefore, we deemed the collinearity of the model
within acceptable parameters.
To assess the population impact of equalising statin prescribing across ethnic groups, we
applied 2011 census ethnicity proportions [28] to the estimated UK population of people with
type 2 diabetes [29] and assumed a lifetime ASCVD risk of 62% [30], giving 213,900 and 94,116
expected ASCVD events in people of South Asian and African/African Caribbean ethnicity
with type 2 diabetes, respectively. Assuming that 51% of people of South Asian ethnicity with
expected ASCVD events receive statins (as we have found), and a relative reduction in ASCVD
risk of 37% with high-potency statin treatment [7], we would expect 40,362 ASCVD events to
be prevented AU : ForthenumbersofASCVDevenoverthelifetimesofpeopleofSouthAsianethnicitycurrentlyaffectedbytype2diabetesintheUK:tsprevented; Irecommendindicatingoverwhattimeperiod:under current prescribing practices over the lifetimes of people f South Asian
ethnicity currently affected by type 2 diabetes in the UK. For people of African/African Carib-
bean ethnicity (whose statin initiation rate was 41%), we would expect 14,277 prevented events
over the lifetimes of people of African/ African Caribbean ethnicity currently affected by type 2
diabetes in the UK. However, applying our observed statin prescribing rate of 59% for people of
Fig 2. Associations between ethnicity and guideline-indicated statin initiation after type 2 diabetes diagnosis:
Sub-group analyses. Sub-group analyses by (a) total cholesterol/high-density lipoprotein cholesterol ratio (TC/HDL)
tertile, (b) London practice locationAU : InthelegendforFig2; IchangedLondonresidencetoLondonpracticelocation:Ifthisisnotcorrect; pleaseedit:, (c) time period of National Institute for Health a d Care Excellence (NICE)
guidelines, and (d) ethnic sub-group. Data are HRs (marker) and 95% CIs (capped lines) adjusted for age, gender,
deprivation, smoking, healthcare usage, TC/HDL, BMI, prevalent comorbidity, medication usage, and
antihypertensive usage, from multilevel models accounting for intra-practice clustering. European ethnicity = referent
category, i.e., HR for people of European ethnicity = 1.
https://doi.org/10.1371/journal.pmed.1003672.g002
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European ethnicity to the populations of South Asian and African/African Caribbean ethnicity,
we would expect 46,694 and 20,545 events to be prevented. Therefore, by equalising statin initia-
tion rates to those in the European group, an additional 6,331 and 6,268 ASCVD events, respec-
tively, could be prevented in South Asian and African/African Caribbean people with type 2
diabetes. Using more conservative assumptions—i.e., statin adherence of 60% [31] and use of
low-potency statins resulting in a 22% reduction in ASCVD events (as reported by the Heart
Protection Study in diabetes, which assessed the efficacy of simvastatin 40 mg over 4.6 years of
follow-up [32])—yields corresponding numbers of events prevented of 2,259 and 2,236 for peo-
ple of South Asian and African/African Caribbean ethnicities, respectively. Of note, all esti-
mated numbers of events prevented are likely to be conservative, since they are modelled on 4-
to 5-year reductions in ASCVD, as reported in trials, rather than lifetime risk reductions.
Discussion
We report markedly lower guideline-indicated statin initiation for people of African/African
Caribbean ethnicity with type 2 diabetes than those of European ethnicity. A more modest
reduction was seen for people of South Asian ethnicity. Even after accounting for differences
in baseline cholesterol, other ASCVD risk factors, sociodemographics, and healthcare usage,
statin initiation was still 24% and 9% lower, respectively, than for the European group. More-
over, time to statin initiation was longer for South Asian and African/African Caribbean
groups than for people of European ethnicity.
Our finding of marked statin underprescribing for primary prevention in people with type 2
diabetes of African/African Caribbean ethnicity is commensurate with previous work from the
UK [5,6] and the US [11–14]. Arguably, inequalities in prescribing may be anticipated in the US
fee-for-service healthcare system, where inter-ethnic socioeconomic disparities influence health
insurance coverage, and thus may place non-white ethnic groups at a disadvantage [12]. How-
ever, it is striking that we see similar levels of inequality in the UK, where healthcare is free at
the point of delivery. UK studies have also reported statin prescribing to be similar [5] or higher
[6] in South Asian than European people, patterns substantiated by studies of statin prescribing
in non-diabetic [33] or secondary prevention populations [34,35]. Our findings for the South
Asian group are not dissimilar, given that the ethnic difference was small and attenuated in the
London-practice sub-group, and for the final time period of the study. Nevertheless, the dis-
tinctly lower statin initiation rate we show for the Bangladeshi population in our secondary
analysis of ethnic sub-groups is discordant and should be interpreted with caution, though it
may be related to the markedly younger age of diabetes onset or to the high levels of deprivation
we found in this sub-group; in support of our work, several other studies report inequitable pre-
scribing for this group [36,37]. Also in keeping with the results suggested by our secondary anal-
yses, O’Keeffe et al. found greater levels of appropriate prescribing in London compared to
most other areas of the country [38], and Finnikin et al. described greater levels of guideline-
adherent prescribing after the introduction of the 2014 NICE guideline [39].
We were unable to fully account for the ethnic differences in statin initiation shown by this
study despite assessing the role of sociodemographics, ASCVD risk factors, healthcare usage,
comorbidity, and polypharmacy; the sole explanatory factor identified was the lower baseline
cholesterol in the African/African Caribbean and South Asian groups compared to the Euro-
pean group. Therefore, some of the underprescription may have resulted from primary care
physicians making prescribing decisions based on cholesterol value alone, rather than consid-
ering overall ASCVD risk, especially in the pre-2014 era of treating to cholesterol targets in
diabetes. Nevertheless, ethnic differences were still not fully explained by adjustment for cho-
lesterol, and we also found marked underprescription for African/African Caribbean people at
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the highest tertile of TC/HDL—there was no obvious explanation for this. Further explanatory
factors, such as deprivation, may have been obscured by residual confounding due to misclassifi-
cation of deprivation level; the IMD is derived at area level only, thus is not a direct measure of
an individual’s social circumstances or wealth [23]. We could not reliably distinguish between
people being offered a statin and declining, and not being offered a statin per se, and reasons for
statin declinature were infrequently recorded, especially for African/African Caribbean people
(4%), so it is impossible to pinpoint exact reasons for underprescribing. A portion of it may be
due to patient choice, which may not be adequately informed [40]. If underprescribing is at the
general practitioner’s discretion, this may be due to inadequate knowledge of ethnic differences
in ASCVD risk (e.g., that whilst African/African Caribbean people have lower risk of coronary
disease, their risk of stroke far surpasses that of Europeans, regardless of cholesterol levels [3]);
an improvement in this over time may explain the smaller ethnic differences in the last years of
the study. The broader concept of structural racism, encompassing all of the factors above, is an
increasingly recognised source of health inequalities [41].
Key strengths of this study include a large, nationally representative population, with indi-
vidual-level electronic prescribing data—in contrast to previous UK studies, which were
restricted to London practices [5] or utilised practice-level [42,43] or self-report data [6]. The
innovative approach of accounting for temporal changes in national prescribing guidelines
enabled us to examine prescribing differences only in the population of people with type 2 dia-
betes in whom guidelines indicated statin use, reducing selection bias. Unlike previous work,
we adjusted for a range of individual- and practice-level covariates [5,6]. Our novel use of a
longitudinal, rather than cross-sectional [5,6], design enhanced sample selection precision,
improved outcome ascertainment, and allowed quantification of prescribing delays. Given
that almost all UK primary care prescriptions are recorded electronically, it is likely that out-
come ascertainment of statin prescriptions was near complete. However, as with all studies of
electronic health records, some selection bias is likely, as more data on covariates such as BMI
and smoking status are recorded for regular attenders, who in turn may have more health
problems [44]. Correspondingly, our comparison of the complete case analysis sample versus
those excluded due to missing data showed lower consultation rates and antihypertensive use
in the latter group. Nevertheless, no differences in sociodemographics or other healthcare
usage factors were found, and as this bias is likely to be equally present across ethnic groups,
its impact on associations between ethnicity and prescribing is probably minimal. This study
used only data from people with a recorded ethnicity of interest; we believe the complete case
assumption (conditional independence between missingness and outcome) is more plausible
than the missing at random assumption needed for multiple imputation, since missingness of
ethnicity in primary care data is likely to be associated with ethnicity itself.
By equalising statin initiation rates between people of South Asian or African/African
Caribbean ethnicity and those of European ethnicity, up to an additional 12,600 ASCVD
events in people with type 2 diabetes could be prevented. Therefore, further research must
urgently seek explanations for underprescribing of statins, particularly in African/African
Caribbean people. If our findings are corroborated, a nationwide strategy for identifying pre-
scribing inequities [25] and providing targeted education and prescribing interventions, fol-
lowed by re-audit until equitability is achieved, is imperative and could lead to the prevention
of substantial cardiovascular morbidity.
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